New to Stocktwits?
Get access to real time conversations, investor sentiment, price predictions and customized watchlists.
Advertisement|Remove ads.
Advertisement|Remove ads.
©2025 StockTwits, Inc. All rights reserved.
Market Data by Xignite and BATS BZX Real-Time Price.
Earnings Call Data by Quartr. Crypto data provided by Coingecko. Earnings Summary data by Fiscal.ai
Stocktwits, Inc. (“Stocktwits”) is not a securities broker-dealer, investment adviser, or any other type of financial professional. No content on the Stocktwits platform should be considered an offer, solicitation of an offer, or advice to buy or sell securities or any other type of investment or financial product.
By using the Stocktwits platform, you understand and agree that Stocktwits does not provide investment advice, recommend any security, transaction, or order, issue securities, produce or provide research. For additional disclosures, please see here.
Bullish
67
High
63
/filters:format(webp)/images/default_avatar_14_large.png){kind=avatar}
/filters:format(webp)/images/default_avatar_1_large.png){kind=avatar}
I can’t overstate how positive I am about $IXHL. For me, it’s simply a matter of time.
If success means making money from this stock, I’ve already done that. Enough to be happy. But now, my conviction runs deeper than asking when this will pump.
After taking the time to dig into patents, explore competitors, and truly understand what Incannex is building - the value of their drug, its unique benefits, and its potential to solve a real human problem - I see something rare. Potentially a unicorn in the making. Think $GWPH, $IMMU, $PCYC, $NBIX…
The bears might call this “hopium” or try to slander it, but I don’t care. This will outgrow them.
It baffles me why some people spend their energy being negative or betting against it. They might win a day, a week, even a month, but in the long run they’ll lose.
Can’t wait to see Incannex flourish and to have been here early. 🫶 Bullish
Show More
1
5
/filters:format(webp)/production/10295455/large-1754087349.png)
I can’t overstate how positive I am about $IXHL. For me, it’s simply a matter of time.
If success means making money from this stock, I’ve already done that. Enough to be happy. But now, my conviction runs deeper than asking when this will pump.
After taking the time to dig into patents, explore competitors, and truly understand what Incannex is building - the value of their drug, its unique benefits, and its potential to solve a real human problem - I see something rare. Potentially a unicorn in the making. Think $GWPH, $IMMU, $PCYC, $NBIX…
The bears might call this “hopium” or try to slander it, but I don’t care. This will outgrow them.
It baffles me why some people spend their energy being negative or betting against it. They might win a day, a week, even a month, but in the long run they’ll lose.
Can’t wait to see Incannex flourish and to have been here early. 🫶 Bullish
Show More
1
1
18
$CRDF Go look at Pharmacyclics at the beginning of 2000, its subsequent decline as doubt set in on Imbruvica, and how it ended a decade later. Yes it's possible for $CRDF to be at 52 week lows, and then one day be acquired for 100x - market doubt can exist and also be wrong at the same time, such was the case with $PCYC. When you have a therapy like Onvansertib generating 100% tumor shrinkage in mCRC it's going to be hard to ignore over time. $PFE most certainly is watching carefully.
/filters:format(webp)/images/default_avatar_4_large.png){kind=avatar}
@look2theblue then why is price at 52 week lows. Dont be an ostrich. Do you not think that big money would be here if there was a decent chance of 10x? I am as hopeful as anyone but give me a break, look at the obvious. Retail traders get so lost in their heads that we forget that whatever is going to happen, was already priced in months ago by those who already knew. Some just cant get themselves and see the big picture. Worse yet, I see it but frozen in denial and belief that it will change. Its why 95% of retail traders fail in the long run. Emotion and belief...feelings have no place in the trading/ short tetm investing world. Commodore exits and somehow we still make excuses and believe we know something the institutions dont...lol. let us all get real.
Show More
2
3
/filters:format(webp)/images/default_avatar_3_large.png){kind=avatar}
1
3
/filters:format(webp)/production/6257110/large-1739137684.png)
$MDGL Rezdiffra sales by quarter post FDA approval versus $PCYC 's Imbruvica. These are not apples to apples bios. PCYC was acquired by $ABBV for $20.2B in May 2015.
We could not find any other like bio with MDGL's actual revenues to date profile.
Again these are not apples to apples as Imbruvica was in multiple late-stage trials at the time of the acquisition (and later had multiple label expansions post M&A). Imbruvica was also oncology focused.
Can anyone share why these may be comparables?
4
3
/filters:format(webp)/production/4308601/large-1756127194.png)
/filters:format(webp)/production/9900280/large-1740696767.png)
/filters:format(webp)/images/default_avatar_11_large.png){kind=avatar}
$SLS
i bought 5K shares of VKTX about 3 years ago for $2.50/share and sold a few months later for $6.50/share (making 20K). Didn't wait until $85/share!!! NEVER AGAIN!!! SLS all the way to a buy out! Bullish
1
7
/filters:format(webp)/production/3214480/large-1597037818.png)
3
8
/filters:format(webp)/production/8731352/large-1702629181.png)
$SLS
I am totally satisfied with the SP at the moment, 1 good PR about
‐ Arbitration
- 009 data
‐ PIVOT data
- FDA update 009 handling
- 009 data....
It looks very good....
1
1
9
/filters:format(webp)/production/1637935/large-1614184473.png)
$PCYC $SLS $XBI $SMMT $CORT SLS Next up. Big whales loading up here before the next Binary PR. "Volume precedes price" intensity of buying and record breaking volume in last 3 weeks:
3 Binary Catalysts, you have to be in it to win it:
1. GPS Regal Pivotal Registrational phase 3 study data in AML CR2 where MOS has reached 19 months now compared to BAT 6-8 Months historically.
2. SLS009 complete phase 2 data set with Accelerated Approval by FDA.
3. Outright BO.
💎🙌❤️🩹💉 Bullish
2
$PCYC $SLS $XBI $SMMT $CORT SLS Next up. Big whales loading up here before the next Binary PR. "Volume precedes price" intensity of buying and record breaking volume in last 3 weeks:
3 Binary Catalysts, you have to be in it to win it:
1. GPS Regal Pivotal Registrational phase 3 study data in AML CR2 where MOS has reached 19 months now compared to BAT 6-8 Months historically.
2. SLS009 complete phase 2 data set with Accelerated Approval by FDA.
3. Outright BO.
💎🙌❤️🩹💉 Bullish
1
13
/filters:format(webp)/production/1593847/large-1761984774.png)
$SLS 26,000% GAIN in $PCYC for Ibrutinib, A Blood cancer treatment. - Launch Based on P3 Data.
Lock and Load as Many of these cheap SLS's as You Can, Something Similar is about to Happen Here.
-- Investment Opportunity of a Lifetime - as sure a thing there is in the Market.
Today's trading action, is another tell - Green, SLS was Green, While the Bio Market got Bludgeoned $XBI -7%.
Same with SLS Climbing, Plus 70% Since the IDMC UNBLINDED ACTUAL Phase 3 Overall Survival and Immune Response was Released, which told the few of us Paying Attention,
Gps is Getting FDA Approval to a $6B TAM
which means SLS is worth Billions - Certainly a S _ _ _ Ton more than the current $160M Micro Cap.
IMO NFA Do your DD
Show More
1
1
18
$SLS 26,000% GAIN in $PCYC for Ibrutinib, A Blood cancer treatment. - Launch Based on P3 Data.
Lock and Load as Many of these cheap SLS's as You Can, Something Similar is about to Happen Here.
-- Investment Opportunity of a Lifetime - as sure a thing there is in the Market.
Today's trading action, is another tell - Green, SLS was Green, While the Bio Market got Bludgeoned $XBI -7%.
Same with SLS Climbing, Plus 70% Since the IDMC UNBLINDED ACTUAL Phase 3 Overall Survival and Immune Response was Released, which told the few of us Paying Attention,
Gps is Getting FDA Approval to a $6B TAM
which means SLS is worth Billions - Certainly a S _ _ _ Ton more than the current $160M Micro Cap.
IMO NFA Do your DD
Show More
/filters:format(webp)/production/8193659/large-1743808568.png)
$SLS
Pharmacyclics (PCYC)
• Early Days:
• Stock Price: Traded under $1 in the mid-2000s.
• Struggles: Multiple failed drugs and clinical setbacks made it look like a write-off.
• Dilution: Raised capital repeatedly to stay afloat—standard for small biotechs.
• Turnaround:
• Breakthrough: Developed ibrutinib (Imbruvica), a BTK inhibitor for blood cancers.
• Clinical Success: Strong Phase III results and FDA approval in 2013 transformed the company’s prospects.
• Outcome:
• Acquisition: Acquired by AbbVie in 2015 for $21 billion, or $261.25 per share, a massive gain from its sub-$1 lows.
⸻
Other Notable Examples:
Avexis (AVXS)
• Focus: Gene therapy for spinal muscular atrophy.
• Volatility: Priced around $8 post-IPO in 2016, traded like a risky bet.
• Outcome: Acquired by Novartis in 2018 for $8.7 billion ($218 per share). Bullish
Show More
1
1
11
/filters:format(webp)/production/2974748/large-1729081871.png)
5
/filters:format(webp)/production/9441197/large-1743089614.png)
Also: $PHAT may get bought for a nice price. That honestly is their best outcome- even if less than you and other bulls want. As little as I know about your CCO, other employees at your company are top notch. Terrie never impressed me much - she was no Nadim Ahmed ( $CGEM ) or Jackie Fouse (formerly $AGIO ) or Shawn Tomasello (she made a ton off of Genentech, $CELG , $KITE , and $PCYC ). She chooses winners. 🚀
$PHAT would be lucky to get bought soon for $12. $AMGN or $GSK should buy them; or they should buy $KPTI ot $RDHL . They are desperate 💰
/filters:format(webp)/production/8506868/large-1730886040.png)
$CRVS some chatter about SMMT and their move. I'd like to just point out something for people to chew on. Their drug is a VEGF covalent,,,, "Lenvima is a kinase inhibitor targeting VEGF receptors and many other proteins involved in cancer." specifically this antibody drug conjugant binds to Tcells. $CRVS is a T CELL inhibitor & even shown evidence of converting a T17 cell to T Reg......Corvus...would you please step to the front of the line and give Duggan a bi!@ch slap for what he did to you at $PCYC inhibit the tcell and no need for Lenvima!
2
4
/filters:format(webp)/production/1407707/large-1707689340.png)